Scalper1 News
Cardiac device maker Edwards Lifesciences (EW) beat analysts’ Q3 estimates and raised guidance late Monday, sending its stock up more than 6% in after-hours trading. Edwards’ earnings totaled $1.07 a share, up 23% from the year-earlier quarter and beating analysts’ consensus by 9 cents, according to Thomson Reuters. Revenue rose 1.3% to $615.5 million, about $17 million above consensus. The “underlying” growth rate, i.e. excluding the Scalper1 News
Scalper1 News